Christopher Coffey, director of the Clinical Trials Statistical and Data Management Center and professor of biostatistics in the University of Iowa College of Public Health, and Cristina Tilley, Claire Ferguson-Carlson Faculty Fellow in Law and professor in the UI College of Law, will deliver the
Older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who were not good candidates for the standard treatment of intensive chemotherapy had a median overall survival (OS) of 6.5 years on an alternate regimen of dasatinib and blinatumomab.
Combo Treatment Sans Chemotherapy Effective for Ph+ ALL Elderly miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Model Predicts Risk of Non-Adherence to Aromatase Inhibitor miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant (pre-operative) pembrolizumab.